No FDA approval decision on any classic psychedelic occurs in 2026; MDMA remains in post-CRL remediation.

MDMA (the active ingredient in ecstasy, being studied for PTSD) got rejected by the FDA last year and is still fixing the problems the agency flagged. No other psychedelic has even submitted a full application for approval. With no approvals possible, the legal status of these drugs can't change through the medical route either.

My division requires durability and functional-unblinding fixes. No NDA is decision-ready this year. The docket confirms no legislative shortcut exists.